China
GenScript Biotech and T-MAXIMUM Biotech Form Strategic Alliance on cGMP sgRNA
PISCATAWAY, N.J. and NANJING, China, Aug. 9, 2023 /PRNewswire/ -- GenScript Biotech, the world's leading life-science research tools and services provider, and T-MAXIMUM Biotech, a biotechnology company pioneering universal cell therapies, have formed a strategic collaboration agreement to enable the development of T-MAXIMUM's development CAR-T cell therapy using GenScript's CRISPR nucleic acid reagents.
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer’s Disease Treatment ADLARITY® in Multiple Markets Across Asia
BOSTON & TAIPEI, Taiwan--(BUSINESS WIRE)--Corium, LLC (“Corium”), a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical (1795:TT; “Lotus”), a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
Adlai Norty has filed F-1 with the US SEC for the company to be listed in the US in late July
Adlai Nortye, headquartered in Hangzhou, China and with an office in New Jersey, USA, has filed F-1 with the US SEC for the company to be listed in the US in late July. Cantor is the lead underwriter and CLSA is a co-manager
上海打响“医保支持医药创新”第一枪，全国会否跟进？
Shanghai Municipal Medical Insurance Bureau and seven other departments jointly issued policies for Shanghai to further improve the diversified payment mechanism. Shanghai has become the first province to use medical insurance policies to support pharmaceutical innovation.
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the US Food and Drug Administration (FDA) has provided a complete response to its Biologics License Application (BLA) resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD) and requires more data to support marketing approval.
House committee quizzes BlackRock and MSCI on China investments
The US House of Representatives China committee has accused BlackRock and MSCI of profiting from investments that help the Chinese military and undermine American values and security.
Universe Pharmaceuticals INC Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares
Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 1, 2023, notifying the Company that it is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market.
Burning Rock Provides Second Quarter 2023 Business Updates and Schedules Earnings Release on August 31, 2023
Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the second quarter of 2023 before the U.S. market opens on August 31, 2023.
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of an Assignment Agreement (the "Agreement") with Mundipharma International Corporation Limited ("MICL"), Mundipharma Medical Company ("MMCo"), and Acrotech Biopharma Inc. ("Acrotech") for the commercialization of FOLOTYN® (Pralatrexate) in the People's Republic of China ("China").
U.S. FDA Grants Orphan Drug Designation to ABM-1310 for the Treatment of Patients with Glioblastoma Harboring BRAF V600 Mutation
ABM Therapeutics (ABM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABM-1310, a novel small molecule BRAF inhibitor developed by the company, for the treatment of patients with glioblastoma (GBM) bearing BRAF V600 mutation.
